WO2001013909A3 - Compositions and methods for treating opiate intolerance - Google Patents
Compositions and methods for treating opiate intolerance Download PDFInfo
- Publication number
- WO2001013909A3 WO2001013909A3 PCT/US2000/023264 US0023264W WO0113909A3 WO 2001013909 A3 WO2001013909 A3 WO 2001013909A3 US 0023264 W US0023264 W US 0023264W WO 0113909 A3 WO0113909 A3 WO 0113909A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- active compound
- compositions
- opiate
- methylnalorphine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU69344/00A AU6934400A (en) | 1999-08-25 | 2000-08-24 | Compositions and methods for treating opiate intolerance |
CA002380524A CA2380524A1 (en) | 1999-08-25 | 2000-08-24 | Compositions and methods for treating opiate intolerance |
EP00957776A EP1206264A2 (en) | 1999-08-25 | 2000-08-24 | Compositions and methods for treating opiate intolerance |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15073999P | 1999-08-25 | 1999-08-25 | |
US60/150,739 | 1999-08-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001013909A2 WO2001013909A2 (en) | 2001-03-01 |
WO2001013909A3 true WO2001013909A3 (en) | 2001-05-25 |
Family
ID=22535805
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/023264 WO2001013909A2 (en) | 1999-08-25 | 2000-08-24 | Compositions and methods for treating opiate intolerance |
Country Status (5)
Country | Link |
---|---|
US (2) | US6455537B1 (en) |
EP (1) | EP1206264A2 (en) |
AU (1) | AU6934400A (en) |
CA (1) | CA2380524A1 (en) |
WO (1) | WO2001013909A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9180125B2 (en) | 2008-09-30 | 2015-11-10 | Wyeth, Llc | Peripheral opioid receptor antagonists and uses thereof |
US9526723B2 (en) | 2008-03-21 | 2016-12-27 | The University Of Chicago | Treatment with opioid antagonists and mTOR inhibitors |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6274591B1 (en) * | 1997-11-03 | 2001-08-14 | Joseph F. Foss | Use of methylnaltrexone and related compounds |
US20030158220A1 (en) * | 1997-11-03 | 2003-08-21 | Foss Joseph F. | Use of methylnaltrexone and related compounds to treat chronic opioid use side effects |
US20030022909A1 (en) * | 2001-06-05 | 2003-01-30 | University Of Chicago | Use of methylnaltrexone to treat immune suppression |
US20050011468A1 (en) * | 2002-02-04 | 2005-01-20 | Jonathan Moss | Use of methylnaltrexone in treating gastrointestinal dysfunction in equines |
CA2475305A1 (en) * | 2002-02-04 | 2004-02-19 | Jonathan Moss | Use of methylnaltrexone in treating gastrointestinal dysfunction in equines |
US20040087606A1 (en) * | 2002-11-01 | 2004-05-06 | Voorhees Marc E. | Shivering suppression during cooling to lower body temperature |
JP2006522819A (en) * | 2003-04-08 | 2006-10-05 | プロジェニックス ファーマシューティカルズ,インコーポレーテッド | Combination therapy of constipation combined with laxatives and peripheral opioid antagonists |
BRPI0409128A (en) * | 2003-04-08 | 2006-03-28 | Progenics Pharm Inc | use of peripheral opioid antagonists, especially methylnaltrexone to treat irritable bowel syndrome |
EP2368553B1 (en) * | 2003-04-08 | 2014-12-31 | Progenics Pharmaceuticals, Inc. | Pharmaceutical formulations containing methylnaltrexone |
EP1845989A1 (en) * | 2005-01-20 | 2007-10-24 | Progenics Pharmaceuticals, Inc. | Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction |
WO2006096626A2 (en) | 2005-03-07 | 2006-09-14 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US8524731B2 (en) | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
AR057325A1 (en) | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | SYNTHESIS OF (S) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES |
AR057035A1 (en) | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SYNTHESIS OF (R) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES |
US20080194611A1 (en) * | 2005-06-03 | 2008-08-14 | Alverdy John C | Modulation of Cell Barrier Dysfunction |
WO2008064353A2 (en) * | 2006-11-22 | 2008-05-29 | Progenics Pharmaceuticals, Inc. | 7,8-saturated-4,5-epoxy-morphinanium analogs |
WO2008136865A2 (en) * | 2006-11-22 | 2008-11-13 | Progenics Pharmaceuticals, Inc. | (s)-n-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs |
ES2540551T3 (en) | 2007-03-29 | 2015-07-10 | Wyeth Llc | Peripheral opioid receptor antagonists and uses thereof |
JP5461386B2 (en) | 2007-03-29 | 2014-04-02 | プロジェニックス ファーマシューティカルズ,インコーポレーテッド | Peripheral opioid receptor antagonists and uses thereof |
MX351611B (en) | 2007-03-29 | 2017-10-20 | Wyeth Llc | Crystal forms of (r) -n-methylnaltrexone bromide and uses thereof. |
CN101827819B (en) * | 2007-08-09 | 2013-06-12 | 伦斯勒理工学院 | Quaternary opioid carboxamides |
US8748448B2 (en) | 2007-10-18 | 2014-06-10 | Aiko Biotechnology | Combination analgesic employing opioid agonist and neutral antagonist |
WO2009051824A2 (en) * | 2007-10-18 | 2009-04-23 | Aiko Biotechnology | Combination analgesic employing opioid and neutral antagonist |
EP2730578A1 (en) | 2008-02-06 | 2014-05-14 | Progenics Pharmaceuticals, Inc. | Preparation and use of (r),(r)-2,2'-bis-methylnal trexone |
EP2421868A4 (en) * | 2009-04-24 | 2012-08-01 | Univ Brock | Processes for the preparation of morphinane and morphinone compounds |
US20140021864A1 (en) * | 2010-09-01 | 2014-01-23 | Wen-Yung Liao | Functional control adapter for light generating device |
CN104873455B (en) | 2010-12-22 | 2023-09-12 | 普渡制药公司 | Coated Tamper Resistant Controlled Release Dosage Forms |
US9233073B2 (en) | 2010-12-23 | 2016-01-12 | Purdue Pharma L.P. | Tamper resistant solid oral dosage forms |
EA201500742A1 (en) | 2013-02-05 | 2015-12-30 | Пердью Фарма Л.П. | PHARMACEUTICAL COMPOSITIONS PROTECTED FROM NON-GOAL USE |
US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0113632A1 (en) * | 1982-12-30 | 1984-07-18 | Sanofi S.A. | Process for the preparation of halogen methylates of levallorphane, and peripheral narcotic antagonist pharmaceutical compositions containing them |
US4719215A (en) * | 1986-03-07 | 1988-01-12 | University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
US5756514A (en) * | 1996-08-22 | 1998-05-26 | Larijani; Ghassem E. | Methods for treatment and prevention of drug-induced pruritus with serotonin type 3 receptor antagonists |
WO1999022737A1 (en) * | 1997-11-03 | 1999-05-14 | Arch Development Corporation | Use of methylnaltrexone and related compounds |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3254088A (en) | 1961-03-14 | 1966-05-31 | Lewenstein | Morphine derivative |
US3773955A (en) | 1970-08-03 | 1973-11-20 | Bristol Myers Co | Analgetic compositions |
US4466968A (en) | 1980-11-24 | 1984-08-21 | Dermall, Ltd. | Method for prophylaxis or treatment of emesis and nausea |
GB9423588D0 (en) * | 1994-11-22 | 1995-01-11 | Glaxo Wellcome Inc | Compositions |
-
2000
- 2000-08-24 CA CA002380524A patent/CA2380524A1/en not_active Abandoned
- 2000-08-24 EP EP00957776A patent/EP1206264A2/en not_active Withdrawn
- 2000-08-24 AU AU69344/00A patent/AU6934400A/en not_active Abandoned
- 2000-08-24 WO PCT/US2000/023264 patent/WO2001013909A2/en not_active Application Discontinuation
- 2000-08-25 US US09/648,496 patent/US6455537B1/en not_active Expired - Fee Related
-
2002
- 2002-08-08 US US10/215,305 patent/US20030018043A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0113632A1 (en) * | 1982-12-30 | 1984-07-18 | Sanofi S.A. | Process for the preparation of halogen methylates of levallorphane, and peripheral narcotic antagonist pharmaceutical compositions containing them |
US4719215A (en) * | 1986-03-07 | 1988-01-12 | University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
US5756514A (en) * | 1996-08-22 | 1998-05-26 | Larijani; Ghassem E. | Methods for treatment and prevention of drug-induced pruritus with serotonin type 3 receptor antagonists |
WO1999022737A1 (en) * | 1997-11-03 | 1999-05-14 | Arch Development Corporation | Use of methylnaltrexone and related compounds |
Non-Patent Citations (5)
Title |
---|
BIANCHETTI A. ET AL: "Quaternary derivatives of narcotic antagonists: Stereochemical requirements at the chiral nitrogen for in vitro and in vivo activity.", LIFE SCIENCES, (1983) 33/SUPPL. 1 (415-418). CODEN: LIFSAK, XP000980615 * |
CLARK S J ET AL: "EVALUATION OF OPIOID-INDUCED ANTINOCICEPTIVE EFFECTS IN ANESTHETIZED AND CONSCIOUS ANIMALS", BRITISH JOURNAL OF PHARMACOLOGY, vol. 95, no. 1, 1988, pages 275 - 283, XP000980392, ISSN: 0007-1188 * |
FERREIRA S H ET AL: "IS METHYL NALORPHINIUM THE PROTOTYPE OF AN IDEAL PERIPHERAL ANALGESIC", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 99, no. 1, 1984, pages 23 - 30, XP000980657, ISSN: 0014-2999 * |
KIANG J.G. ET AL: "Tolerance to morphine bradycardia in the rat.", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, (1983) 226/1 (187-191). CODEN: JPETAB, XP000980656 * |
NOTARNICOLA A. ET AL: "Relative ability of N- methyl nalorphine and N-methyl levallorphan to prevent antinociception and intestinal transit inhibition in morphine treated rats.", LIFE SCIENCES, (1983) 33/SUPPL. 1 (481-484). CODEN: LIFSAK, XP000980614 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9526723B2 (en) | 2008-03-21 | 2016-12-27 | The University Of Chicago | Treatment with opioid antagonists and mTOR inhibitors |
US9180125B2 (en) | 2008-09-30 | 2015-11-10 | Wyeth, Llc | Peripheral opioid receptor antagonists and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
EP1206264A2 (en) | 2002-05-22 |
CA2380524A1 (en) | 2001-03-01 |
US6455537B1 (en) | 2002-09-24 |
WO2001013909A2 (en) | 2001-03-01 |
US20030018043A1 (en) | 2003-01-23 |
AU6934400A (en) | 2001-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001013909A3 (en) | Compositions and methods for treating opiate intolerance | |
WO2000021515A3 (en) | Intranasal codeine for the rapid suppression of cough and rapid relief of pain | |
WO2003080022A3 (en) | Analgesics for nasal administration | |
EP1700601A3 (en) | Use of dextromethorphan and an oxidase inhibitor for weaning patients from narcotics and anti-despressants | |
CA2301017A1 (en) | Use of propyl gallate to increase bioavailability of orally administered pharmaceutical compounds | |
CA2274074A1 (en) | Novel compounds with analgesic effect | |
HU219332B (en) | Synergetic medicaments containing trans-(+)-2-[(dimethylamino)-methyl]-1-(3-methoxiphenyl)-cyclohexanol and acetaminophen | |
NZ508037A (en) | A stabilized antihistamine syrup containing aminopolycarboxylic acid as stabilizer | |
NO996310L (en) | Compositions and procedures for reducing respiratory depression and concomitant side effects of mu-opioid compounds | |
WO2002019999A3 (en) | Compositions for treating sexual dysfunction, containing an no-donor and an antioxidant | |
CA2428160A1 (en) | Compositions for antitumor treatment containing ecteinascidin 743 | |
WO2002070524A3 (en) | N-but-3-enyl norbuprenorphine and its use as analgesic | |
AU2313297A (en) | Transdermally administered dextromethorphan as antitussive agent | |
WO2000071108A3 (en) | Methods for treatment of asthma using s-oxybutynin | |
WO2001041705A3 (en) | Novel methods for the treatment and prevention of dizziness and pruritus | |
WO1991018606A3 (en) | Orally active nonaddicting analgesics | |
CA2394471A1 (en) | External preparation for treating pruritus | |
EP0906757A3 (en) | Analgesic composition comprising moxonidine and an opioid analgesic agent | |
WO2000026185A3 (en) | Omeprazole solution and method of using same | |
GEP20043252B (en) | Use of NOS Inhibitors by New Pharmaceutical Designation for Treatment of Chronic and Acute Pains with Mammalians | |
WO2001043734A3 (en) | Transdermal administration of phenylpropanolamine | |
WO2002041841A3 (en) | Compositions for adhesion prevention | |
WO2007069033A3 (en) | Pharmaceutical compositions comprising dexibuprofen, an opiate analgesic and paracetamol | |
WO2003095453A1 (en) | Compounds against helicobacter activity | |
MY133596A (en) | Compound and method for the treatment of pain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2380524 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 69344/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000957776 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000957776 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000957776 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |